Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P26045
UPID:
PTN3_HUMAN
Alternative names:
Protein-tyrosine phosphatase H1
Alternative UPACC:
P26045; A0AUW9; E7EN99; E9PGU7
Background:
Tyrosine-protein phosphatase non-receptor type 3, also known as Protein-tyrosine phosphatase H1, plays a pivotal role at the nexus of membrane and cytoskeleton interactions. It exhibits tyrosine phosphatase activity, crucial for cellular signaling pathways.
Therapeutic significance:
Understanding the role of Tyrosine-protein phosphatase non-receptor type 3 could open doors to potential therapeutic strategies. Its involvement in key cellular processes highlights its potential as a target in drug discovery.